Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)
University of California, Irvine Medical Center · Roswell Park Comprehensive Cancer Center · +23 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
675
total citations
- FWCI
- 39.62
- Percentile
- 100%
- References
- 39
Citations per year
Authors
23- KSKrishnansu S. TewariCorresponding
University of California, Irvine Medical Center
- MWMichael W. Sill
Roswell Park Comprehensive Cancer Center, University at Buffalo, State University of New York
- RTRichard T. Penson
Massachusetts General Hospital
- HHHelen Huang
University at Buffalo, State University of New York, Roswell Park Comprehensive Cancer Center
- LMLois M. Ramondetta
The University of Texas MD Anderson Cancer Center
Topics & keywords
Topics
Keywords
- Medicine
- Gynecologic oncology
- Bevacizumab
- Interim analysis
- Internal medicine
- Adverse effect
- Topotecan
- Cervical cancer
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.